Xin Lang Zheng Quan·2025-09-23 03:22Group 1 - The core point of the article highlights the recent stock performance of Nuo Cheng Jian Hua, which saw a decline of 2.00% on September 23, with a trading price of 26.92 CNY per share and a total market capitalization of 475.04 billion CNY [1] - Nuo Cheng Jian Hua has experienced a significant stock price increase of 119.22% year-to-date, but has seen a slight decline of 1.43% over the past five trading days and 6.85% over the past 20 days [1] - The company primarily engages in the research, production, and commercialization of biopharmaceuticals, focusing on unmet clinical needs in oncology and autoimmune diseases, with a product pipeline that includes several investigational drugs [1] Group 2 - As of June 30, 2025, Nuo Cheng Jian Hua reported a revenue of 731 million CNY, representing a year-on-year growth of 74.26%, while the net profit attributable to shareholders was -30.09 million CNY, showing an increase of 88.51% compared to the previous period [2] - The company operates within the pharmaceutical and biotechnology sector, specifically in chemical pharmaceuticals and formulations, and is involved in various concept sectors including biopharmaceuticals and innovative drugs [2] - The number of shareholders increased by 13.80% to 15,200 as of June 30, 2025, indicating growing interest in the company's stock [2] Group 3 - Institutional holdings show that as of June 30, 2025, the top ten circulating shareholders include several funds, with notable increases in holdings from certain funds, while others have decreased their positions [3] - The sixth largest shareholder, China Europe Medical Health Mixed A, increased its holdings by 3.98 million shares, while new shareholders have entered the top ten list [3] - The changes in institutional holdings reflect a dynamic investment landscape for Nuo Cheng Jian Hua, with some funds increasing their stakes while others have exited [3]